Hossein Shateri, Babak Manafi, Amir Hossein Yazdi, Sayed Mostafa Hosseini
{"title":"Elevated asprosin levels in epicardial adipose tissue: Implications for coronary artery disease.","authors":"Hossein Shateri, Babak Manafi, Amir Hossein Yazdi, Sayed Mostafa Hosseini","doi":"10.34172/jcvtr.026.33554","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study investigates the role of the adipokine asprosin in coronary artery disease (CAD) by comparing its levels in epicardial adipose tissue (EAT) and serum between individuals with and without CAD. Asprosin is known to be involved in conditions such as insulin resistance and obesity, both of which are risk factors for CAD.</p><p><strong>Methods: </strong>The study included 25 CAD patients and 25 non-CAD patients undergoing open-heart surgery for valve issues. EAT samples were collected during surgery, and the mRNA levels of the FBN-1 gene were measured using qRT-PCR, while the protein levels of asprosin in both EAT and serum were determined using the ELISA method.</p><p><strong>Results: </strong>The results showed that the mRNA level of FBN-1 in the EAT of CAD patients was significantly higher than that in the control group (<i>P</i><0.001). Additionally, asprosin protein levels were significantly elevated in both the EAT (<i>P</i><0.003) and serum (<i>P</i><0.027) of CAD patients compared to non-CAD individuals.</p><p><strong>Conclusion: </strong>These findings suggest that asprosin may play a critical role in the pathogenesis of CAD, particularly through its increased presence in EAT and serum. The study highlights the potential of asprosin as a biomarker for CAD, though further research is needed to fully understand its mechanisms in the progression of the disease.</p>","PeriodicalId":15207,"journal":{"name":"Journal of Cardiovascular and Thoracic Research","volume":"18 1","pages":"32-37"},"PeriodicalIF":1.4000,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309332/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular and Thoracic Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jcvtr.026.33554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This study investigates the role of the adipokine asprosin in coronary artery disease (CAD) by comparing its levels in epicardial adipose tissue (EAT) and serum between individuals with and without CAD. Asprosin is known to be involved in conditions such as insulin resistance and obesity, both of which are risk factors for CAD.
Methods: The study included 25 CAD patients and 25 non-CAD patients undergoing open-heart surgery for valve issues. EAT samples were collected during surgery, and the mRNA levels of the FBN-1 gene were measured using qRT-PCR, while the protein levels of asprosin in both EAT and serum were determined using the ELISA method.
Results: The results showed that the mRNA level of FBN-1 in the EAT of CAD patients was significantly higher than that in the control group (P<0.001). Additionally, asprosin protein levels were significantly elevated in both the EAT (P<0.003) and serum (P<0.027) of CAD patients compared to non-CAD individuals.
Conclusion: These findings suggest that asprosin may play a critical role in the pathogenesis of CAD, particularly through its increased presence in EAT and serum. The study highlights the potential of asprosin as a biomarker for CAD, though further research is needed to fully understand its mechanisms in the progression of the disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
